GEn1E Lifesciences Granted Exclusive Option to License University of Maryland, Baltimore’s Selective P38 Kinase Inhibitor Access to University of Maryland, Baltimore’s broadly applicable P38 Kinase inhibitor technology offers GEn1E the potential to enter the clinic with an acute lung injury/acute respiratory distress...